Amylyx Pharmaceuticals
Amylyx Pharmaceuticals
AMLX
NASDAQ
3.97
USD
1.53%
About
Amylyx Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the discovery and development of treatments for neurodegenerative diseases. The Company is focused on the development and commercialization of its product candidate: AMX0035 for the treatment of Wolfram syndrome and for the treatment of progressive supranuclear palsy, and AMX0114, the Company’s antisense oligonucleotide targeting calpain-2 for the treatment of amyotrophic lateral sclerosis (ALS).
AMX0035 is a dual-unfolded protein response (UPR)-Bax apoptosis inhibitor composed of PB and TURSO (also known as TUDCA). The Company’s Avexitide is an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist that has been evaluated in five clinical trials for post-bariatric hypoglycemia (PBH) and has also been studied in congenital hyperinsulinism (HI), two indications characterized by hyperinsulinemic hypoglycemia..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 598.4K |
| Three Month Average Volume | 34.0M |
| High Low | |
| Fifty-Two Week High | 22.03 USD |
| Fifty-Two Week Low | 1.575 USD |
| Fifty-Two Week High Date | 01 Sep 2023 |
| Fifty-Two Week Low Date | 17 Jun 2024 |
| Price and Volume | |
| Current Price | 2.22 USD |
| Beta | -100,000 |
| Relative Price Change | |
| Four Week Relative Price Change | 4.03% |
| Thirteen Week Relative Price Change | 20.59% |
| Twenty-Six Week Relative Price Change | -89.21% |
| Fifty-Two Week Relative Price Change | -91.78% |
| Year-to-Date Relative Price Change | -87.26% |
| Price Change | |
| One Day Price Change | 4.72% |
| Thirteen Week Price Change | 29.07% |
| Twenty-Six Week Price Change | -88.13% |
| Five Day Price Change | -0.45% |
| Fifty-Two Week Price Change | -89.70% |
| Year-to-Date Price Change | -84.92% |
| Month-to-Date Price Change | 7.77% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 6.40154 USD |
| Book Value Per Share (Most Recent Quarter) | 3.83832 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 6.40154 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 3.83832 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -0.89089 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 5.44047 USD |
| Revenue Per Share (Trailing Twelve Months) | 4.34307 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | 0.70396 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -2.45185 USD |
| Normalized (Last Fiscal Year) | 0.70396 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | 0.73282 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -2.4395 USD |
| Including Extraordinary Items (Last Fiscal Year) | 0.70396 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -2.45185 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 5.4848 USD |
| Cash Per Share (Most Recent Quarter) | 4.55077 USD |
| Cash Flow Per Share (Last Fiscal Year) | 0.7195 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -2.39485 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -0.86576 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -100,000 |
| Cash Flow Revenue (Trailing Twelve Months) | -20 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -54.35% |
| Pretax Margin (Last Fiscal Year) | 14.26% |
| Pretax Margin (5 Year) | -99,999.99% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | 93.32% |
| Gross Margin (Trailing Twelve Months) | 84.64% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | 10.19% |
| Operating Margin (Trailing Twelve Months) | -59.50% |
| Operating Margin (5 Year) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | 12.94% |
| Net Profit Margin (Trailing Twelve Months) | -55.52% |
| Net Profit Margin (5 Year) | -99,999.99% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -99,999.99% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -101.04% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | 55.71% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | 736.74% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -99,999.99% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | -439.55% |
| EPS Change (Trailing Twelve Months) | -98.78% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 0 |
| Price to Tangible Book (Most Recent Quarter) | 1 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | 14 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -309,812,000 |
| Net Debt (Last Fiscal Year) | -371,362,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 0 |
| Price to Sales (Trailing Twelve Months) | 1 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | 3 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 0 |
| Price to Book (Most Recent Quarter) | 1 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | 0.00% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | 5 |
| Quick Ratio (Most Recent Quarter) | 5 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -4 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 6 |
| Current Ratio (Most Recent Quarter) | 5 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | 10.7M |
| Free Cash Flow (Trailing Twelve Months) | -59,556,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | 10.84% |
| Return on Assets (Trailing Twelve Months) | -42.22% |
| Return on Assets (5 Year) | -99,999.99% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | 12.73% |
| Return on Equity (Trailing Twelve Months) | -51.22% |
| Return on Equity (5 Year) | -99,999.99% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | 12.63% |
| Return on Investment (Trailing Twelve Months) | -50.91% |
| Return on Investment (5 Year) | -99,999.99% |